Zetomipzomib - Kezar Life Sciences
Alternative Names: KZR-616Latest Information Update: 10 Oct 2024
Price :
$50 *
At a glance
- Originator Onyx Pharmaceuticals
- Developer Everest Medicines; Kezar Life Sciences
- Class Anti-inflammatories; Antianaemics; Antirheumatics; Cyclopentanes; Hepatoprotectants; Morpholines; Small molecules; Urologics
- Mechanism of Action Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Autoimmune hepatitis; Dermatomyositis; Lupus nephritis; Polymyositis; Systemic lupus erythematosus
- Preclinical Haemophagocytic lymphohistiocytosis
- No development reported Autoimmune disorders
Most Recent Events
- 04 Oct 2024 The US FDA places a clinical hold on IND application of zetomipzomib for Lupus nephritis
- 30 Sep 2024 Adverse events data from a phase IIa PORTOLA trial in Autoimmune hepatitis released by Kezar Life Sciences
- 30 Sep 2024 Adverse events data from a phase IIb PALIZADE trial in Lupus nephritis released by Kezar Life Sciences